Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation - PubMed (original) (raw)

. 2004 Jan 1;103(1):242-51.

doi: 10.1182/blood-2003-04-1048. Epub 2003 Sep 11.

Affiliations

• PMID: 12969979
• DOI: 10.1182/blood-2003-04-1048

Free article

Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation

Katja Brocke-Heidrich et al. Blood. 2004.

Free article

Abstract

Interleukin 6 (IL-6) is a growth and survival factor for multiple myeloma cells. As we report here, the IL-6-dependent human myeloma cell line INA-6 responds with a remarkably rapid and complete apoptosis to cytokine withdrawal. Among the antiapoptotic members of the B-cell lymphoma-2 (Bcl-2) family of apoptosis regulators, only myeloid cell factor-1 (Mcl-1) was slightly induced by IL-6. Overexpression studies demonstrated, however, that IL-6 does not exert its survival effect primarily through this pathway. The IL-6 signal transduction pathways required for survival and the target genes controlled by them were analyzed by using mutated receptor chimeras. The activation of signal transducer and activator of transcription 3 (Stat3) turned out to be obligatory for the survival of INA-6 cells. The same held true for survival and growth of XG-1 myeloma cells. Gene expression profiling of INA-6 cells by using oligonucleotide microarrays revealed many novel IL-6 target genes, among them several genes coding for transcriptional regulators involved in B-lymphocyte differentiation as well as for growth factors and receptors potentially implicated in autocrine or paracrine growth control. Regulation of most IL-6 target genes required the activation of Stat3, underscoring its central role for IL-6 signal transduction. Taken together, our data provide evidence for the existence of an as yet unknown Stat3-dependent survival pathway in myeloma cells.

PubMed Disclaimer

Similar articles

• Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach.
  French JD, Tschumper RC, Jelinek DF. French JD, et al. Leukemia. 2002 Jun;16(6):1189-96. doi: 10.1038/sj.leu.2402516. Leukemia. 2002. PMID: 12040452
• Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival.
  Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, Tai YT, Shringarpure R, Catley L, Senaldi G, Gramatzki M, Anderson KC. Burger R, et al. Br J Haematol. 2003 Dec;123(5):869-78. doi: 10.1046/j.1365-2141.2003.04686.x. Br J Haematol. 2003. PMID: 14632778
• In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.
  Chatterjee M, Hönemann D, Lentzsch S, Bommert K, Sers C, Herrmann P, Mathas S, Dörken B, Bargou RC. Chatterjee M, et al. Blood. 2002 Nov 1;100(9):3311-8. doi: 10.1182/blood-2002-01-0102. Blood. 2002. PMID: 12384432
• Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors.
  Hirano T, Ishihara K, Hibi M. Hirano T, et al. Oncogene. 2000 May 15;19(21):2548-56. doi: 10.1038/sj.onc.1203551. Oncogene. 2000. PMID: 10851053 Review.
• Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation.
  Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, Otsuyama K, Zheng X, Kawano MM. Ishikawa H, et al. Leuk Lymphoma. 2003 Sep;44(9):1477-81. doi: 10.3109/10428190309178767. Leuk Lymphoma. 2003. PMID: 14565647 Review.

Cited by

• The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma.
  Zhu B, Ju S, Chu H, Shen X, Zhang Y, Luo X, Cong H. Zhu B, et al. Oncol Lett. 2018 May;15(5):6094-6106. doi: 10.3892/ol.2018.8157. Epub 2018 Mar 2. Oncol Lett. 2018. PMID: 29731841 Free PMC article. Review.
• New frontiers in the treatment of multiple myeloma.
  Hwang JJ, Ghobrial IM, Anderson KC. Hwang JJ, et al. ScientificWorldJournal. 2006 Dec 6;6:1475-503. doi: 10.1100/tsw.2006.236. ScientificWorldJournal. 2006. PMID: 17160337 Free PMC article. Review.
• Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
  Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P, Podar K, Catley L, Hideshima T, Chauhan D, Caulder E, Neilan CL, Vaddi K, Li J, Gramatzki M, Fridman JS, Anderson KC. Burger R, et al. Mol Cancer Ther. 2009 Jan;8(1):26-35. doi: 10.1158/1535-7163.MCT-08-0149. Mol Cancer Ther. 2009. PMID: 19139110 Free PMC article.
• Novel Interleukin-6 Inducible Gene PDZ-Binding Kinase Promotes Tumor Growth of Multiple Myeloma Cells.
  Ota A, Hanamura I, Karnan S, Inaguma S, Takei N, Lam VQ, Mizuno S, Kanasugi J, Wahiduzzaman M, Rahman ML, Hyodo T, Konishi H, Tsuzuki S, Ikeda H, Takami A, Hosokawa Y. Ota A, et al. J Interferon Cytokine Res. 2020 Aug;40(8):389-405. doi: 10.1089/jir.2020.0111. Epub 2020 Jul 23. J Interferon Cytokine Res. 2020. PMID: 32721246 Free PMC article.
• STAT2 Is a Pervasive Cytokine Regulator due to Its Inhibition of STAT1 in Multiple Signaling Pathways.
  Ho J, Pelzel C, Begitt A, Mee M, Elsheikha HM, Scott DJ, Vinkemeier U. Ho J, et al. PLoS Biol. 2016 Oct 25;14(10):e2000117. doi: 10.1371/journal.pbio.2000117. eCollection 2016 Oct. PLoS Biol. 2016. PMID: 27780205 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal